110 related articles for article (PubMed ID: 30604411)
1. Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer.
Du J; He Y; Wu W; Li P; Chen Y; Hu Z; Han Y
J Pharm Pharmacol; 2019 Feb; 71(2):196-205. PubMed ID: 30604411
[TBL] [Abstract][Full Text] [Related]
2. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
[TBL] [Abstract][Full Text] [Related]
3. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells.
Wang X; Zhao J; Huang J; Tang H; Yu S; Chen Y
Biochem Biophys Res Commun; 2012 Aug; 425(1):51-7. PubMed ID: 22820191
[TBL] [Abstract][Full Text] [Related]
4. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
Jiang J; Yuan Z; Sun Y; Bu Y; Li W; Fei Z
Biomed Pharmacother; 2017 Dec; 96():619-625. PubMed ID: 29035827
[TBL] [Abstract][Full Text] [Related]
5. miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells.
Zhang W; Lin J; Wang P; Sun J
J Drug Target; 2017 Feb; 25(2):125-131. PubMed ID: 27633093
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of GEP100 Improved the Growth Inhibition Effect of Erlotinib Through Modulating Mesenchymal Epithelial Transition Process in Pancreatic Cancer.
Xie CG; Sun SL; Wei SM; Xu XM; Shao LM; Chen JM; Cai JT
Pancreas; 2018 Jul; 47(6):732-737. PubMed ID: 29851753
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-127 is aberrantly downregulated and acted as a functional tumor suppressor in human pancreatic cancer.
Yu Y; Liu L; Ma R; Gong H; Xu P; Wang C
Tumour Biol; 2016 Oct; 37(10):14249-14257. PubMed ID: 27571739
[TBL] [Abstract][Full Text] [Related]
9. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2.
Jin Q; Li XJ; Cao PG
Tohoku J Exp Med; 2016 Feb; 238(2):143-51. PubMed ID: 26843134
[TBL] [Abstract][Full Text] [Related]
11. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
12. Interaction between microRNA-181a and TNFAIP1 regulates pancreatic cancer proliferation and migration.
Zhang P; Guo Z; Hu R; He X; Jiao X; Zhu X
Tumour Biol; 2015 Dec; 36(12):9693-701. PubMed ID: 26152285
[TBL] [Abstract][Full Text] [Related]
13. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-137 inhibits autophagy and chemosensitizes pancreatic cancer cells by targeting ATG5.
Wang ZC; Huang FZ; Xu HB; Sun JC; Wang CF
Int J Biochem Cell Biol; 2019 Jun; 111():63-71. PubMed ID: 30710750
[TBL] [Abstract][Full Text] [Related]
15. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
Hao J; Yang X; Ding XL; Guo LM; Zhu CH; Ji W; Zhou T; Wu XZ
Sci Rep; 2016 Sep; 6():32809. PubMed ID: 27609096
[TBL] [Abstract][Full Text] [Related]
16. A dysregulated microRNA-26a/EphA2 axis impairs endothelial progenitor cell function via the p38 MAPK/VEGF pathway.
Zuo K; Zhi K; Zhang X; Lu C; Wang S; Li M; He B
Cell Physiol Biochem; 2015; 35(2):477-88. PubMed ID: 25613580
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
[TBL] [Abstract][Full Text] [Related]
18. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p.
Gao ZQ; Wang JF; Chen DH; Ma XS; Yang W; Zhe T; Dang XW
Biomed Pharmacother; 2018 Jan; 97():809-817. PubMed ID: 29112934
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.
Li X; Deng SJ; Zhu S; Jin Y; Cui SP; Chen JY; Xiang C; Li QY; He C; Zhao SF; Chen HY; Niu Y; Liu Y; Deng SC; Wang CY; Zhao G
Oncotarget; 2016 Feb; 7(5):6000-14. PubMed ID: 26755660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
